Meanwhile, molecular evaluation of mutations in the BCOR and BCORL1 genes in the diagnosis of uterine sarcomas overexpressing BCOR is recommended to differentiate high-grade endometrial mesenchymal sarcomas with BCOR fusions from rare adenosarcomas with BCORL1 gene rearrangements and BCORL1-PRR14L fusions, potentially broadening the genetic spectrum of adenosarcomas. The gene discussed is PRR14L; the disease is adenosarcoma.